ReviewBrain : a journal of neurology2016
Emerging therapies for mitochondrial disorders.
Review in Brain : a journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- EVs from Stem Cells Improve Mitochondrial Dysfunction in Neuronal Disorders.Molecular neurobiology · 2025Review
- Peptide-mimetics derived from leucyl-tRNA synthetase are potential agents for the therapy of mt-tRNA related diseases.Frontiers in pharmacology · 2025Article
- Precision mitochondrial medicine.Cambridge prisms. Precision medicine · 2023Review
- Stem cell-derived mitochondria transplantation: A promising therapy for mitochondrial encephalomyopathy.CNS neuroscience & therapeutics · 2021Review
- Microbiota-Mitochondria Inter-Talk: A Potential Therapeutic Strategy in Obesity and Type 2 Diabetes.Antioxidants (Basel, Switzerland) · 2020Review
- Chronic pain is common in mitochondrial disease.Neuromuscular disorders : NMD · 2020Article
- Metabolic effects of bezafibrate in mitochondrial disease.EMBO molecular medicine · 2020Observational
- Article
- Healthy, mtDNA-mutation free mesoangioblasts from mtDNA patients qualify for autologous therapy.Stem cell research & therapy · 2019Article
- Advances in primary mitochondrial myopathies.Current opinion in neurology · 2019Review
- Bezafibrate Upregulates Mitochondrial Biogenesis and Influence Neural Differentiation of Human-Induced Pluripotent Stem Cells.Molecular neurobiology · 2019Article
- Diagnosis of adult-onset MELAS syndrome in a 63-year-old patient with suspected recurrent strokes - a case report.BMC neurology · 2019Article
- Mitochondrial energy generation disorders: genes, mechanisms, and clues to pathology.The Journal of biological chemistry · 2019Review
- Article
- Mitochondrial neurogastrointestinal encephalopathy: a clinicopathological mimic of Crohn's disease.BMC gastroenterology · 2019Article
- The genetic basis of disease.Essays in biochemistry · 2018Review
- Mitochondria as a therapeutic target for common pathologies.Nature reviews. Drug discovery · 2018Review
- Rescue from galactose-induced death of Leigh Syndrome patient cells by pyruvate and NADCell death & disease · 2018Article
- The Bacterial Protein CNF1 as a Potential Therapeutic Strategy against Mitochondrial Diseases: A Pilot Study.International journal of molecular sciences · 2018Article
- KH176 Safeguards Mitochondrial Diseased Cells from Redox Stress-Induced Cell Death by Interacting with the Thioredoxin System/Peroxiredoxin Enzyme Machinery.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mitochondrial disorders are a diverse group of debilitating conditions resulting from nuclear and mitochondrial DNA mutations that affect multiple organs, often including the central and peripheral nervous system. Despite major advances in our understanding of the molecular mechanisms, effective treatments have not been forthcoming. For over five decades patients have been treated with different vitamins, co-factors and nutritional supplements, but with no proven benefit. There is therefore a clear need for a new approach. Several new strategies have been proposed acting at the molecular or cellular level. Whilst many show promise in vitro, the clinical potential of some is questionable. Here we critically appraise the most promising preclinical developments, placing the greatest emphasis on diseases caused by mitochondrial DNA mutations. With new animal and cellular models, longitudinal deep phenotyping in large patient cohorts, and growing interest from the pharmaceutical industry, the field is poised to make a breakthrough.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.